TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study.
Overview
- Graduate School, Dalian Medical University, Dalian 116044, China
- Department of Neurosurgery, Dalian Municipal Central Hospital, Dalian 116033, China; (Z.J.)
- Faculty of Medicine, Dalian University of Technology, Dalian 116024, China
Abstract
Background/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.
Data
Datasets cited
- geo:GSE148842, at NCBI GEO; found in the text, “2.8. Single-Cell Localization”
Data Availability Statement
The raw data supporting the findings of this study are publicly available from the following repositories: TCGA RNA-seq expression and clinical data were downloaded from the Genomic Data Commons (GDC) portal (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 4 authors, 6 keywords, 1 funder, 75 references.
Cite
This paper
Balawi, E., Jiang, Z., Wang, X., & Chen, D. (2026). TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activat
BibTeX
@article{balawi2026tgfb2
author = {Balawi, Ehab and Jiang, Zhicheng and Wang, Xianwei and Chen, Dong},
title = {{TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activat
journal = {Cancers},
year = {2026},
month = jun,
volume = {18},
number = {13},
pages = {2092},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
issn = {2072-6694},
doi = {10.3390/
url = {https://
pmid = {42449636},
pmcid = {PMC13359701}
}
RIS
TY - JOUR
AU - Balawi, Ehab
AU - Jiang, Zhicheng
AU - Wang, Xianwei
AU - Chen, Dong
TI - TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activat
T2 - Cancers
J2 - Cancers (Basel)
PY - 2026
DA - 2026/
VL - 18
IS - 13
SP - 2092
SN - 2072-6694
PB - Multidisciplinary Digital Publishing Institute (MDPI)
DO - 10.3390/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3390/
"type": "article-journal",
"title": "TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activat
"container-title": "Cancers",
"author": [
{
"family": "Balawi",
"given": "Ehab"
},
{
"family": "Jiang",
"given": "Zhicheng"
},
{
"family": "Wang",
"given": "Xianwei"
},
{
"family": "Chen",
"given": "Dong"
}
],
"container-title-short":
"volume": "18",
"issue": "13",
"page": "2092",
"DOI": "10.3390/
"PMID": "42449636",
"PMCID": "PMC13359701",
"ISSN": "2072-6694",
"publisher": "Multidisciplinary Digital Publishing Institute (MDPI)",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
27
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1371/journal.pone.0295346
- Integrated bioinformatics analysis and experimental validation identified CDCA families as prognostic biomarkers and sensitive indicators for rapamycin treatment of glioma.Journal: PloS oneIn common: other condition, 10 references
- [2] doi:10.3390/biomedicines13112640 [code]
- A Prognostic Neuromodulation-Related Gene Signature Identifies Immunomodulation and Tumour-Associated Hallmarks in Glioblastoma.Journal: BiomedicinesIn common: other condition, 9 references
- [3] doi:10.1038/s41698-025-01260-6 [code]
- A machine learning-defined cellular senescence signature systematically enhances prognostication and guides immunotherapy strategies for the treatment of gliomas.Journal: NPJ precision oncologyIn common: other condition, 10 references
- [4] doi:10.1038/s41420-022-00883-z
- Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation.Journal: Cell death discoveryIn common: other condition, 9 references
- [5] doi:10.1080/07853890.2024.2405079
- Necroptosis-based glioblastoma prognostic subtypes: implications for TME remodeling and therapy response.Journal: Annals of medicineIn common: NCBI GEO GSE148842, other condition, 4 references
- [6] doi:10.1016/j.isci.2022.105276 [code]
- Integrative genomic analysis facilitates precision strategies for glioblastoma treatment.Journal: iScienceIn common: other condition, 9 references
- [7] doi:10.1186/s40478-023-01651-5
- Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages.Journal: Acta neuropathologica communicationsIn common: genetics / omics, other condition, 8 references
- [8] doi:10.3389/fimmu.2026.1752553
- Metabolic reprogramming of glioma-associated macrophages identifies detoxification and energetic macrophages as drivers of immunosuppression and therapeutic vulnerability.Journal: Frontiers in immunologyIn common: genetics / omics, other condition, 7 references
- [9] doi:10.3390/biology12050648 [code]
- Identification of Prominent Genes between 3D Glioblastoma Models and Clinical Samples via GEO/
TCGA/ CGGA Data Analysis. Journal: BiologyIn common: other condition, 7 references - [10] doi:10.1016/j.ebiom.2022.104239
- Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM.Journal: EBioMedicineIn common: genetics / omics, other condition, 7 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
